ACCESSWIRE
04 Feb 2023, 05:31 GMT+10
SAN FRANCISCO, CA / ACCESSWIRE / February 3, 2023 / Hagens Berman urges Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) investors who suffered significant losses to submit your losses now.
Class Period: Oct. 6, 2020 - Oct. 28, 2022
Lead Plaintiff Deadline: Mar. 20, 2023
Visit: www.hbsslaw.com/investor-fraud/YMAB
Contact An Attorney Now: YMAB@hbsslaw.com
844-916-0895
Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Securities Fraud Class Action:
The litigation focuses on Y-mAbs' past assurances that its Biologics License Application ('BLA') for I-omburtamab for the treatment of central nervous system/leptomeningeal metastases in pediatric patients with neuroblastoma was 'on track.'
The complaint alleges that Defendants assured investors that, pursuant to a series of meetings and other communications between Y-mAbs and the FDA, progress was being made toward meeting the FDA's requirement that the company demonstrate substantial evidence of effectiveness for FDA approval of omburtamab. The complaint further alleges that Defendants did not disclose that: (1) the FDA repeatedly advised the company that effectiveness of omburtamab could not be objectively established based on a comparison of its study to an external cohort comprised of data from the Central German Childhood Cancer Registry ('CGCCR'); and (2) the company's Study 101 was neither sufficiently advanced nor indicative of efficacy to justify FDA approval.
Investors learned the truth on Oct. 26, 2022, when the FDA Oncologic Drugs Advisory Committee ('ODAC') published its briefing document which identified FDA scientists' concerns about the totality of evidence submitted by Y-mAbs in support of its BLA. Among other things, the briefing document revealed that the FDA informed Y-mAbs on multiple occasions that the CGCCR data external control may not be fit-for-purpose as a direct comparator for overall survival data.
Then, on Oct. 28, 2022, Y-mAbs announced that ODAC unanimously voted that the company did not provide sufficient evidence to conclude that omburtamab improves overall survival.
These events sent the price of Y-mAbs shares crashing lower.
'We're focused on investors' losses and proving Y-mAbs lied about data submitted in support of its BLA, its communications with the FDA, and the commercial prospects for I-omburtamab,' said Reed Kathrein, the Hagens Berman partner leading the investigation.
If you invested in Y-mAbs and have significant losses, or have knowledge that may assist the firm's investigation, click here to discuss your legal rights with Hagens Berman.
Whistleblowers: Persons with non-public information regarding Y-mAbs should consider their options to help in the investigation or take advantage of the SEC Whistleblower program. Under the new program, whistleblowers who provide original information may receive rewards totaling up to 30 percent of any successful recovery made by the SEC. For more information, call Reed Kathrein at 844-916-0895 or email YMAB@hbsslaw.com.
# # #
About Hagens Berman
Hagens Berman is a global plaintiffs' rights complex litigation law firm focusing on corporate accountability through class-action law. The firm is home to a robust securities litigation practice and represents investors as well as whistleblowers, workers, consumers and others in cases achieving real results for those harmed by corporate negligence and fraud. More about the firm and its successes can be found at hbsslaw.com. Follow the firm for updates and news at @ClassActionLaw.
Contact:
Reed Kathrein, 844-916-0895
SOURCE: Hagens Berman Sobol Shapiro LLP
Get a daily dose of San Francisco Star news through our daily email, its complimentary and keeps you fully up to date with world and business news as well.
Publish news of your business, community or sports group, personnel appointments, major event and more by submitting a news release to San Francisco Star.
More InformationBrittney Griner and the Phoenix Mercury will attempt once again to win a game in her Texas homecoming when they ...
Randy Vasquez allowed two hits in 5 2/3 innings for his first career win as the host New York Yankees ...
Colombo [Sri Lanka], June 9 (ANI): China's absence from the Sri Lankan debt restructuring meeting in Washington in April indicates ...
Washington [US], June 9 (ANI): Cuba has agreed to allow China to construct a surveillance facility on the island that ...
© Provided by Xinhua The International Tokyo Toy Show, which runs from Thursday to Sunday, is expected to bring together ...
© Provided by Xinhua TIANJIN, June 9 (Xinhua) -- Li Guanglin treats his pet dog, a Golden Retriever, to high-end ...
WASHINGTON D.C.: The Federal Aviation Administration has said that a drone sighting disrupted some flights at Pittsburgh International Airport this ...
PORTLAND, Oregon: A federal trial has begun in Portland, Oregon examining the constitutionality of a stringent gun control law approved ...
PHILADELPHIA, Pennsylvania: Philadelphia Mayor Jim Kenney and members of the city's historical commission have been sued by a group which ...
LANSING, Michigan: Michigan's Department of Natural Resources said by a wildfire in the state has burned through more than 3 ...
ISTANBUL, Turkey: In an interview with Reuters, Willie Walsh, director-general of the International Air Transport Association, (IATA), said airlines are ...
SACRAMENTO, California: Sixteen migrants from Venezuela and Colombia, who had entered the United States through Texas, were transported to California ...